Jupiter Neurosciences (NASDAQ: JUNS), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, has closed its securities purchase agreement for the sale of 7,142,858 shares of common stock in a registered direct offering, generating gross proceeds of approximately $2.0 million. D. Boral Capital LLC acted as the exclusive placement agent for the offering, which was conducted pursuant to the company’s effective shelf registration statement on Form S-3 declared effective by the U.S. Securities and Exchange Commission on April 24, 2026.
The capital raise comes at a pivotal time for Jupiter as it advances its lead program, JOTROL(TM) — a proprietary, enhanced bioavailability resveratrol formulation currently in a Phase IIa clinical trial for Parkinson’s disease. The company also commercializes Nugevia(TM), a consumer longevity supplement, and recently acquired the U.S. rights to ALA-002, a next-generation, patented psychedelic new chemical entity (NCE). This acquisition strengthens Jupiter’s CNS pipeline and positions the company to capitalize on evolving U.S. regulatory policies around psychedelics.
The offering underscores investor confidence in Jupiter’s therapeutic approach targeting neuroinflammation, a key driver of CNS disorders. With additional funding, the company can accelerate clinical development and potentially bring novel treatments to market. For the cannabis and psychedelic industry, Jupiter’s progress highlights the growing convergence of traditional biopharma and psychedelic science, as companies seek to develop patentable, FDA-approved therapies. The successful close of this offering may signal increased capital market support for psychedelic-focused biotechs, especially those with clear regulatory pathways.
For more information on the offering, visit the full press release at https://ibn.fm/o5A0w. Details about Jupiter Neurosciences and its pipeline are available at www.jupiterneurosciences.com.
